Jennifer Rutzen
Acute Care · Lansing, MINPI 1679108500
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.7% of the total across 379 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 31 manufacturers reported payments, led by AstraZeneca at 28.2% of the total. 2025 is the largest year on record at $2,177, more than ten times the $79 reported in 2021. Among acute care clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 379 payments — averaging $18.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Boehringer Ingelheim$787
- Mylan Specialty L.p.$758
- GSK$747
- Regeneron Healthcare Solutions, Inc.$372
- Insmed, Inc.$296
- plus $2K from 25 others
What the payments were for
- Food & beverage$7,03298%
- Education$1652%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 98 | $2,027 |
| Boehringer Ingelheim | 33 | $787 |
| Mylan Specialty L.p. | 37 | $758 |
| GSK | 51 | $747 |
| Regeneron Healthcare Solutions, Inc. | 15 | $372 |
| Insmed, Inc. | 32 | $296 |
| Philips North America LLC | 14 | $256 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $209 |
| Amgen | 9 | $158 |
| Mallinckrodt Hospital Products Inc. | 9 | $155 |
| Viatris Specialty LLC | 10 | $150 |
| Sanofi | 5 | $137 |
| Verona Pharma, Inc. | 11 | $136 |
| Electromed, Inc. | 9 | $129 |
| United Therapeutics Corporation | 4 | $120 |
| Inspire Medical Systems, Inc. | 2 | $115 |
| Axsome Therapeutics, Inc. | 4 | $100 |
| Sanofi-aventis U.S. LLC | 1 | $95 |
| Harmony Biosciences LLC | 4 | $89 |
| Jazz Pharmaceuticals Inc. | 3 | $63 |
| Actelion Pharmaceuticals US, Inc. | 3 | $53 |
| Pulmonx Corporation | 2 | $51 |
| Grifols USA, LLC | 3 | $50 |
| Paratek Pharmaceuticals, Inc. | 2 | $30 |
| Penumbra, Inc. | 2 | $27 |
| Bayer | 1 | $18 |
| La Jolla Pharmaceutical Company | 1 | $15 |
| Gilead | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Melinta Therapeutics, LLC | 1 | $13 |
| Inogen, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,197 in reported general payments places this provider in the 95th percentile of 567 acute care providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 460 | $515,956 |
| OfevNintedanib Esylate | 21 | $267,001 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 83 | $100,130 |
| Spiriva RespimatTiotropium Bromide | 86 | $82,738 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 75 | $58,233 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 70 | $56,059 |
| Breo ElliptaFluticasone/Vilanterol | 59 | $39,592 |
| SymbicortBudesonide/Formoterol Fumarate | 72 | $25,778 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 51 | $23,094 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 512 | $18,634 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 94 | $18,373 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 18 | $10,395 |
| Incruse ElliptaUmeclidinium Bromide | 18 | $10,371 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 19 | $9,478 |
| Arnuity ElliptaFluticasone Furoate | 27 | $7,240 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $747 | $631,393639 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $787 | $416,193195 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere, Pulmicort Flexhaler | $2,027 | $137,800185 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 567 acute care providers in Michigan.
Other acute care in Lansing
- Andrew PalmerLansing$9K
- Bridgette ArnalLansing$2K
- Janet WymanDetroit$103K
- Stephanie Mellon ReppenDetroit$57K
- Ashley WozniakLivonia$26K
- Julia BriggsBirch Run$16K
- Candise LovePort Huron$14K
- Janette GuertinPort Huron$14K
- Gregory AliNovi$13K
- Angela BrennanDearborn Heights$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.